Statement: Both the primary trial and the secondary trial at least partly administer their interventions intravenously.
Primary_evidence: INTERVENTION 1:    Suramin and Paclitaxel   Suramin will be infused weekly over 30 minutes. Four hours after the completion of the suramin infusion the 1 hour infusion of paclitaxel will begin.
Secondary_evidence: INTERVENTION 1:    Ipatasertib and Paclitaxel   Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination. INTERVENTION 2:    Placebo and Paclitaxel   Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.